Reassurance from second trimester sonographic placental scan for pregnancies complicated by abnormal first trimester biomarkers

• Published in: The journal of maternal-fetal & neonatal medicine p. 1
• Main Authors: Aviram, Amir, Jones, Sara L, Huang, Tianhua, Satkunaratnam, Abheha, Melamed, Nir, Mei-Dan, Elad
• Format: Journal Article
• Language: English
• Published: England 01.01.2022
• Subjects: fetal growth restriction; Placental scan; first trimester screening; risk prediction; ultrasound
• ISSN: 1476-4954
• DOI: 10.1080/14767058.2022.2040013

Enhanced first trimester aneuploidy screening (eFTS) combines serum biomarkers and ultrasound. Abnormal biomarkers are associated with placental complications, such as fetal growth restriction (FGR). We aimed to evaluate whether a Midtrimester placental scan can provide reassurance regarding FGR in women with abnormal eFTS biomarkers. We conducted a retrospective cohort study of women who had eFTS and delivered at a single referral center. Women with abnormal biomarkers had a mid-trimester scan of the placenta (morphologic assessment, fetal biometry and uterine artery pulsatility index). We compared pregnancies with abnormal eFTS biomarkers and normal placental scans (study group) with those who had normal eFTS biomarkers (control group). A total of 6,514 women were included, of whom 343 (5.3%) comprised the study group. Women in the study group had an increased risk of hypertensive disorders of pregnancy [(aOR)1.96(95%CI 1.21-3.16)], and preterm birth <37 weeks [aOR1.98(95%CI 1.33-2.95)] compared to the control group. Yet, their neonates were not at higher risk for FGR <3 , 5 , or 10 percentile [aOR1.16(95%CI 0.83-1.63), 1.14(95%CI 0.70-1.87), and 0.47(95%CI 0.17-1.27), respectively]. A normal second trimester placental scan provided reassurance regarding the risk of FGR in women at high risk based on abnormal eFTS biomarkers.